InMed Pharmaceutical

IN
Delayed Toronto Stock Exchange - 04/03 09:55:43 pm
0.205CAD
-6.82%
Income Statement Evolution
Annual Income Statement Data
Actuals in M CAD Estimates in M CAD
Fiscal Period June 2019 2020 (e)
Sales - -
EBITDA -13,5 -14,4
Operating profit (EBIT) -13,6 -14,1
Pre-Tax Profit (EBT) -13,3 -14,2
Net income -13,3 -14,2
P/E ratio -4,13x -2,75x
EPS ( CAD ) -0,08 -0,08
Dividend per Share ( CAD ) - -
Yield - -
Reference price ( CAD ) 0,330 0,220
Announcement Date 09/19/2019
11:30am
-
Finances - Leverage
Actuals in M CAD Estimates in M CAD
Fiscal Period June 2019 2020 (e)
Debt - -
Finance 18,0 3,31
Operating income (EBITDA) -13,5 -14,4
Leverage
(Debt/EBITDA)
- -
Capital Expenditure 0,04 0,05
Free Cash Flow (FCF) - -10,5
Book Value Per Share (BVPS) (  ) - -
Cash Flow per Share (  ) - -
Announcement Date 09/19/2019
11:30am
-
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 38 M CAD -
Entreprise Value (EV) 34,6 M CAD 51,0 M CAD
Valuation 2020e 2021e
P/E ratio (Price / EPS) -2,75x -2,75x
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -2,40x -2,32x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) - -
Operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) - -
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   - -
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -0,88x
Price Earning Ratio
BNA & Dividende